Skip to main content

Table 1 The patient’s treatment process

From: Rare, late onset of immune checkpoint inhibitor-induced type 1 diabetes mellitus in a patient with small-cell lung cancer treated with serplulimab: a case report and review of the literature

Treatment period

Period 1

Period 2

Period 3

Period 4

Period 5

Period 6

Period 7

Period 8

Period 9

Period 10

Period 11

Treatment date

04 May

2022

28 May

2022

20 Jun

2022

28 Jul

2022

19 Aug

2022

09 Oct

2022

16 Jan

2023

13 Feb

2023

22 Mar

2023

27 Apr

2023

06 Aug

2023

Treatment plan

HLX10 300 mg

 + 

CBP

400 mg

 + 

VP-16

360 mg

HLX10 300 mg

 + 

CBP

400 mg

 + 

VP-16

360 mg

HLX10 300 mg

 + 

CBP

400 mg

 + 

VP-16

360 mg

HLX10 300 mg

 + 

CBP

400 mg

 + 

VP-16

360 mg

HLX10 300 mg

 + 

CBP

400 mg

 + 

VP-16

360 mg

HLX10 300 mg

 + 

CBP

400 mg

 + 

VP-16

360 mg

HLX10 300 mg

HLX10 300 mg

HLX10 300 mg

HLX10 300 mg

HLX10 300 mg

  1. HLX10 serplulimab; CBP carboplatin, VP-16 etoposide